




Q4FY24 Balaji Amines Ltd



Balaji Amines Ltd

Pick-up in domestic demand drives sequential performance

CMP INR 2,277*	Target INR 2,643	Potential Upside 16.1%	Market Cap (INR Mn) INR 71,735	Recommendation BUY	Sector Specialty Chemicals
-------------------	---------------------	---------------------------	-----------------------------------	-----------------------	-------------------------------

Result Highlights of Q4FY24:

- Balaji Amines revenue beat our estimate by 4.5% due to strong volume growth in Amines and Amine derivatives. The EBITDA beat our estimate primarily due to a beat in revenue and lower-than-expected operating expenses.
- We believe that the recently launched N-Butyl Amine project will contribute to growth. Additionally, the ongoing Methyl Amine and Di-methyl Ether projects are progressing well and are expected to be long-term growth drivers.
- Currently, the stock is trading at PE multiples of 23.2x/18.0x, based on FY25E/FY26E EPS, respectively. We expect the revenue to grow at 21.7% CAGR and PAT to grow at 39.5% CAGR over FY24-26E. We decrease the target price to INR 2,643/share (previously: INR 2,828) and retain our BUY rating on the stock, implying an FY26E P/E multiple of 21.5x.

MARKET DATA

Shares outs (Mn)	32.4
Equity Cap (INR Mn)	18,932
Mkt Cap (INR Mn)	71,735
52 Wk H/L (INR)	2,735/1,880
Volume Avg (3m K)	113
Face Value (INR)	2
Bloomberg Code	BLA IN

KEY FINANCIALS

INR Millions	FY22	FY23	FY24	FY25E	FY26E
Revenue	23,229	23,554	16,415	20,437	24,320
EBITDA	6,227	6,091	3,237	4,496	5,837
EBITDA margin (%)	26.8%	25.9%	19.7%	22.0%	24.0%
Adj PAT	3,684	3,255	2,049	3,094	3,985
Adj PAT margin (%)	15.9%	13.8%	12.5%	15.1%	16.4%
Adj EPS	113.7	100.5	63.2	95.4	122.9
P/E (x)	19.4	22.0	35.0	23.2	18.0

Source: Company, KRChoksey Research


Sequential improvement in volume and price realization

- For Q4FY24, revenue declined by 12.2% YoY (+8.0% QoQ) to INR 4,139 Mn. For FY24, revenue declined by 30.3% to 16,415 Mn.
- The Q4FY24 saw a total volume growth of about 5.6% YoY (+4.0% QoQ) to 27,984 MT. This was primarily fuelled by robust volume growth in Amines of 33.8% YoY (+15.7% QoQ) to 8,910 MT.
- Amines derivatives volume saw a double-digit growth of 12.4% YoY (4.3% QoQ) to 9,676 MT. Conversely, specialty chemicals saw a decline in volume growth of about 16.4% YoY (-5.3% QoQ) to 9,398 MT.
- On average, price realization per unit for the quarter declined by 16.8% YoY (+3.8% QoQ) to INR 148. The sequential improvement was attributed to a resurgence in domestic demand along with favorable trends in the international market.
- The destocking scenario in India and China has slightly improved, accompanied by a modest increase in pricing. The Methyl Amine project (40,000 MT) is progressing well and is anticipated to be commissioned by the end of December 2024E.

Stable input cost supported profitability margins

- EBITDA for Q4FY24 grew by 4.9% YoY (+31.7% QoQ) to INR 977 Mn. The EBITDA margin expanded 385 bps YoY (+425 bps QoQ) to 23.6%. This improvement can be attributed to stabilized input costs for both raw materials and utilities.
- The PAT grew by 43.5% YoY (+37.8% QoQ) to INR 680 Mn. The PAT margin expanded 638 bps YoY (+356 bps QoQ) to 16.4%.
- The EBITDA margin for FY24 stood at 19.7%, which could have shown an improvement if the specialty chemical segment had performed well. The management has offered guidance for EBITDA margin ranging from 21.0% to 24.0% going forward.

SHARE PRICE PERFORMANCE



MARKET INFO

SENSEX	74,006
NIFTY	22,502

SHARE HOLDING PATTERN (%)

Particulars	Mar-24 (%)	Dec-23 (%)	Sep-23 (%)
Promoters	53.7	53.7	53.7
FIIIs	4.9	4.6	4.5
DIIIs	1.5	1.4	0.9
Others	39.9	40.3	40.9
Total	100.0	100.0	100.0

*Based on previous closing

21.7%

Revenue CAGR between FY24 and FY26E

39.5%

Adj. PAT CAGR between FY24 and FY26E

Balaji Amines Ltd

Key Concall Highlights:


- The recent progress involves the successful launch of **N-Butyl Amines** manufacturing at Unit 4, increasing the yearly production capacity to **15,000 metric tons**.
- **Unit 1 and Unit 3** have been awarded BIS certification for **Morpholin**, elevating the standards of product quality.
- The commissioning of the **Electronic Grade DMC** (Dimethyl Carbonate) plant is scheduled for **FY25E**. Its unique production status and an annual installed capacity of **15,000 MT** make it a **promising prospect for India's EV battery sector**.
- The **Dimethyl Ether (DME)** Unit 4 project is set for **launch by March 2025E**. DME serves as an alternative to LPG and aerosols. Additionally, the Bureau of Indian Standards is considering the advantages of a 20.0% DME blend with LPG.
- The Company is strategizing to establish a **new 20-megawatt solar plant** in collaboration with MIDC in Solapur, Maharashtra.
- Phase 1 entails the installation of an 8-megawatt capacity, projected to become operational by December 2024E.
- The DMC and propylene glycol plant operated at a capacity utilization rate of 30.0% to 40.0%. This lower rate was attributed to the absence of significant projects from lithium battery companies.
- The Company has set up the following projects, 1) N-Methyl Morpholine of about 3,000 tons per annum. 2) N-butyl Thiophosphoric Triamide of about 2,500 tons per annum.
- Isopropylamine will be produced at the current Ethylamine plant in Unit 1 through modifications. However, this plant is not operational because the company needs to establish a new, high-output plant for manufacturing Ethylamines at Unit 4.
- Historically, **revenue experienced modest growth due to decreased price realization**, driven by reduced raw material costs. However, there was an increase in **volume of 8.3%** in FY24 compared to FY23.

Valuation and view:


Balaji Amines reported sequential revenue improvement in Q4FY24, supported by moderate volume growth and a slight uptick in price realization. This was driven by a rebound in domestic demand and favorable international market trends. However, the YoY decline in price realization affected the YoY revenue growth in Q4FY24. We believe that the recently launched N-Butyl Amine project will contribute to growth. Additionally, the ongoing Methyl Amine and Di-methyl Ether projects are progressing well and are expected to be long-term growth drivers. **The stock has remained relatively flat since the last update, with only a 0.5% increase. Currently, the stock is trading at PE multiples of 23.2x/18.0x, based on FY25E/FY26E EPS, respectively. We expect the revenue to grow at 21.7% CAGR and PAT to grow at 39.5% CAGR over FY24-26E. We decrease the target price to INR 2,643/share (previously: INR 2,828) and retain our BUY rating on the stock, implying an FY26E P/E multiple of 21.5x.**

Quarterly trend in charts


Sequential improvement in revenue



EBITDA margin expanded on stable RM cost




Net profit margin expanded on strong operational performance



Source: Company, KRChoksey Research

Balaji Amines Ltd

Segmental volumes in a chart



KEY FINANCIALS

Exhibit 1: Profit & Loss Statement

INR Millions	FY22	FY23	FY24	FY25E	FY26E
Revenues	23,229	23,554	16,415	20,437	24,320
COGS	6,158	12,764	12,612	9,162	11,036
Gross profit	17,071	10,790	3,803	11,274	13,284
Employee cost	966	851	823	1,226	1,459
Other expenses	3,811	4,154	3,323	3,679	4,378
Adj EBITDA	6,227	6,091	3,237	4,496	5,837
Depreciation & amortization	420	456	454	566	720
EBIT before exceptional items	5,807	5,635	2,784	3,930	5,117
Exceptional item	0	0	0	0	0
EBIT	5,807	5,635	2,784	3,930	5,117
Interest expense	171	120	64	60	60
Other income	147	152	296	340	316
PBT	5,783	5,668	3,016	4,210	5,373
Tax	1,604	1,611	693	842	1,114
PAT before MI	4,179	4,057	2,323	3,368	4,259
Minority Interest	495	802	274	274	274
PAT	3,684	3,255	2,049	3,094	3,985
EPS (INR)	113.7	100.5	63.2	95.4	122.9

Source: Company, KRChoksey Research

Exhibit 2: Cash Flow Statement

INR Millions	FY22	FY23	FY24	FY25E	FY26E
Operating Cash Flow	2,196	3,822	2,196	1,991	3,405
Investing Cash Flow	-1,473	-1,863	-1,598	-2,660	-2,684
Financing Cash Flow	-565	-812	-750	7	-60
Net Inc/Dec in cash equivalents	158	1,146	-152	-663	661
Opening Balance	173	331	964	812	149
Closing Balance Cash & Cash Equivalent	331	1,478	812	149	810

Source: Company, KRChoksey Research

Exhibit 3: Key Ratio

Key Ratio	FY22	FY23	FY24	FY25E	FY26E
EBITDA Margins (%)	26.8%	25.9%	19.7%	22.0%	24.0%
Net Profit Margin (%)	15.9%	13.8%	12.5%	15.1%	16.4%
RoE (%)	28.0%	19.2%	10.8%	14.0%	15.3%
RoCE (%)	42.1%	33.0%	16.1%	19.2%	20.7%
RoA (%)	21.1%	16.6%	9.5%	12.8%	14.0%
Debt/Equity (x)	0.08	0.03	0.01	0.01	0.01

Source: Company, KRChoksey Research

Balaji Amines Ltd

Exhibit 4: Balance Sheet

INR Millions	FY22	FY23	FY24	FY25E	FY26E
Property, plant and equipment (PPE)	6,812	7,805	8,961	12,905	15,185
Capital work-in-progress	1,409	1,132	2,026	2,026	2,026
Other financial assets	61	62	71	53	64
Other non-current assets	100	301	415	261	311
Total non-current assets	8,382	9,300	11,492	15,246	17,586
Investment	0	727	0	0	0
Inventories	2,224	3,028	2,869	2,627	3,127
Trade receivables	5,881	3,778	3,194	3,278	3,901
Cash and cash equivalents	331	1,478	812	149	810
Bank balances other than (iii) above	184	886	2,586	2,586	2,586
Other current assets	450	427	506	371	441
Other financial assets	0	5	3	0	0
Total current assets	9,071	10,328	9,970	9,011	10,865
TOTAL ASSETS	17,453	19,628	21,462	24,257	28,450
Equity share capital	65	65	65	65	65
Other equity	12,434	15,478	17,154	20,247	24,232
Non-controlling interests	650	1,439	1,714	1,714	1,714
Total equity	13,149	16,982	18,932	22,026	26,011
Borrowings	576	303	106	106	106
Other financial liabilities	9	10	6	9	10
Provisions	7	18	44	16	19
Deferred tax liabilities (Net)	677	812	875	875	875
Other non-current liabilities	28	10	11	8	10
Total non-current liabilities	1,297	1,153	1,042	1,014	1,021
Borrowings	431	273	91	158	158
Trade payables	1,809	622	778	540	643
Other financial liabilities	630	480	503	417	496
Other current liabilities	83	58	50	51	60
Provisions	0	3	29	3	3
Current tax liabilities (Net)	55	57	37	49	58
Total current liabilities	3,007	1,493	1,487	1,217	1,418
Total liabilities	4,304	2,646	2,529	2,231	2,439
TOTAL EQUITY AND LIABILITIES	17,453	19,628	21,462	24,257	28,450

Source: Company, KRChoksey Research

Balaji Amines Ltd

Balaji Amines Ltd				Rating Legend (Expected over a 12-month period)	
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside
21-May-24	2,277	2,643	BUY	Buy	More than 15%
12-Feb-24	2,201	2,831	BUY	Accumulate	5% – 15%
21-Nov-23	2,030	2,172	ACCUMULATE		
04-Sep-23	2,229	2,803	BUY	Hold	0 – 5%
25-May-23	2,170	3,191	BUY	Reduce	-5% – 0
13-Feb-23	2,180	3,790	BUY	Sell	Less than – 5%
28-Oct-22	3,039	4,313	BUY		

ANALYST CERTIFICATION:

I, Unnati Jadhav (MMS, Finance), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000001295. It is also registered as a Depository Participant with CDSL, CDSL Registration No IN-DP-425-2019.

KRChoksey Shares & Securities Pvt Ltd. and DRChoksey Finserv Private Ltd. (Demerged entity from KRChoksey Shares & Securities Limited) are regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of Research Analysts including preparing and distribution of Research Reports. This research report is prepared and distributed by DRChoksey Finserv Private Ltd in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH00001246. It may be further notified that KRCSSPL carries on the activity of preparation as well as distribution of reports in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000001295.

The information and opinions in this report are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavour to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension follows applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities. KRCSSPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst. It is confirmed that, I, Unnati Jadhav Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions. KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months. KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services. KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report. It is confirmed that, Unnati Jadhav, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report. KRCSSPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such Jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction. Please send your feedback to research.insti@krchoksey.com

In case of any grievances, please write to grievance@krchoksey.com
Visit us at www.krchoksey.com
KRChoksey Shares and Securities Pvt. Ltd.
CIN-U67120MH1997PTC108958
Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001.
Phone: 91-22-6633 5000; Fax: 91-22-6633 8060
Corporate Office: 701-702, DLH Plaza, Opp Shoppers Stop, S V Road, Andheri (W), Mumbai 400 058
Phone: 91-22-66535000
Compliance Officer: Varsha Shinde
Email: varsha.shinde@krchoksey.com